Key result
AH23848 was identified as a potent, specific, orally active thromboxane receptor-blocking drug with a long duration of action in preliminary experiments.
AH23848 is a novel, orally active, and specific thromboxane receptor blocker that may serve as a tool to study the role of thromboxane A2 in vascular diseases.
May enable mechanistic studies of thromboxane A2 in vascular disease; leaves open clinical translation.
Despite numerous suggestions in the literature that thromboxane A2 is involved in a variety of occlusive vascular diseases, no definitive evidence is available. Arguments have been presented to support the view that such evidence can only come from clinical studies with a highly specific thromboxane receptor-blocking drug. We have now identified such a drug, AH23848, in our laboratories. Preliminary experiments with AH23848, ([1 alpha (Z), 2 beta,5 alpha]-(+/-)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-2-(4-morpholin yl)-3-oxocyclopentyl]-4-heptenoic acid), show that it is a potent, specific thromboxane receptor-blocking drug that is orally active and has a long duration of action. It should be a valuable tool in elucidating any physiologic or pathologic role of thromboxane A2.
No takes yet. Share an insight, caveat, or question.
Brittain et al. (1985) studied occlusive vascular diseases. AH23848 was evaluated. AH23848 was identified as a potent, specific, orally active thromboxane receptor-blocking drug with a long duration of action in preliminary experiments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: